EUVIMEDEUVIMED entdecken
LeitlinieOpen Access · CC BY 4.0

SEOM-GG clinical guidelines for the management of germ-cell testicular cancer (2023)

José Angel Arranz Arija, Xavier García Del Muro, Raquel Luque Caro, María José Méndez-Vidal, Begoña Pérez-Valderrama, Jorge Aparicio, Miguel Ángel Climent Durán, Cristina Caballero Díaz, Ignacio Durán, Enrique González-Billalabeitia

Clinical and Translational Oncology · 03.07.2024 · 26 (11) · 2783-2799

DOI: 10.1007/s12094-024-03532-2 ↗

Kurz gefasst

Leitlinie in der Zeitschrift Clinical and Translational Oncology, online erschienen am 03.07.2024. Verfasst von José Angel Arranz Arija und 9 weiteren Autor:innen. Beteiligte Einrichtung: Hospital General Universitario Gregorio Marañón, Madrid, Spain. jarranza.oncomed@gmail.com. Hauptthemen laut MEDLINE: Testicular Neoplasms, Neoplasms, Germ Cell and Embryonal. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 91 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Testicular germ cell tumors are the most common tumors in adolescent and young men. They are curable malignancies that should be treated with curative intent, minimizing acute and long-term side effects. Inguinal orchiectomy is the main diagnostic procedure, and is also curative for most localized tumors, while patients with unfavorable risk factors for recurrence, or those who are unable or unwilling to undergo close follow-up, may require adjuvant treatment. Patients with persistent markers after orchiectomy or advanced disease at diagnosis should be staged and classified according to the IGCCCG prognostic classification. BEP is the most recommended chemotherapy, but other schedules such as EP or VIP may be used to avoid bleomycin in some patients. Efforts should be made to avoid unnecessary delays and dose reductions wherever possible. Insufficient marker decline after each cycle is associated with poor prognosis. Management of residual masses after chemotherapy differs between patients with seminoma and non-seminoma tumors. Patients at high risk of relapse, those with refractory tumors, or those who relapse after chemotherapy should be managed by multidisciplinary teams in experienced centers. Salvage treatment for these patients includes conventional-dose chemotherapy (TIP) and/or high-dose chemotherapy, although the best regimen and strategy for each subgroup of patients is not yet well established. In late recurrences, early complete surgical resection should be performed when feasible. Given the high cure rate of TGCT, oncologists should work with patients to prevent and identify potential long-term side effects of the treatment. The above recommendations also apply to extragonadal retroperitoneal and mediastinal tumors.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Testicular NeoplasmsNeoplasms, Germ Cell and EmbryonalHumansMaleOrchiectomyMedical OncologyAntineoplastic Combined Chemotherapy ProtocolsSalvage TherapyPrognosisNeoplasm Recurrence, LocalSocieties, Medical

Stichwörter der Autor:innen

ChemotherapyGerm cell tumorLong-term survivorsMultidisciplinary teamsSurgeryTesticular cancer

Autor:innen und Institutionen

  • Hospital General Universitario Gregorio Marañón, Madrid, Spain. jarranza.oncomed@gmail.com.
  • Hospital Duran I Reynals, Institut Català D'Oncologia L'Hospitalet (ICO), Barcelona, Spain.
  • Hospital Universitario Virgen de Las Nieves, Instituto de Investigación Biosanitaria Ibs, Granada, Spain.
  • Hospital Universitario Reina Sofía, Córdoba, Spain.
  • Hospital Universitario Virgen del Rocío, Seville, Spain.
  • Hospital Universitario I Politècnic La Fe, Valencia, Spain.

Zitieren

APA

Arranz Arija, J. A., Del Muro, X. G., Caro, R. L., Méndez-Vidal, M. J., Pérez-Valderrama, B., Aparicio, J., Climent Durán, M. Á., Caballero Díaz, C., Durán, I., & González-Billalabeitia, E. (2024). SEOM-GG clinical guidelines for the management of germ-cell testicular cancer (2023). Clinical and Translational Oncology, 26(11), 2783-2799. https://doi.org/10.1007/s12094-024-03532-2

Vancouver

Arranz Arija JA, Del Muro XG, Caro RL, Méndez-Vidal MJ, Pérez-Valderrama B, Aparicio J, et al. SEOM-GG clinical guidelines for the management of germ-cell testicular cancer (2023). Clinical and Translational Oncology. 2024;26(11):2783-2799. doi:10.1007/s12094-024-03532-2

BibTeX
@article{ArranzArija2024,
  author = {Arranz Arija, José Angel and Del Muro, Xavier García and Caro, Raquel Luque and Méndez-Vidal, María José and Pérez-Valderrama, Begoña and Aparicio, Jorge and Climent Durán, Miguel Ángel and Caballero Díaz, Cristina and Durán, Ignacio and González-Billalabeitia, Enrique},
  title = {SEOM-GG clinical guidelines for the management of germ-cell testicular cancer (2023)},
  journal = {Clinical and Translational Oncology},
  year = {2024},
  volume = {26},
  number = {11},
  pages = {2783--2799},
  doi = {10.1007/s12094-024-03532-2}
}
Kostenlos starten →